Trial Profile
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Salivary gland cancer
- Focus Therapeutic Use
- 21 Mar 2018 Status changed from active, no longer recruiting to completed.
- 23 Nov 2015 Results published in the Annals of Oncology
- 12 Dec 2012 Planned end date changed from 1 Aug 2011 to 1 Jan 2013 as reported by ClinicalTrials.gov.